Relmada Therapeutics (RLMD) Income from Non-Controlling Interests (2021 - 2022)
Relmada Therapeutics (RLMD) reported Income from Non-Controlling Interests of -$39.7 million for Q1 2022, down 78.91% year-over-year from -$188.5 million in Q1 2021, and down 78.91% quarter-over-quarter from -$22.2 million in Q1 2021.
Relmada Therapeutics (RLMD) Income from Non-Controlling Interests (2021 - 2022) Analysis & Trends
Relmada Therapeutics (RLMD) has 2 years of Income from Non-Controlling Interests data on file, last reported at -$39.7 million in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.75 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Relmada Therapeutics | 581.07 Mn | 581.07 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | -39.75 Mn |
| Mar 31, 2021 | -22.22 Mn |